Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


China Experts Believe Tainted Heparin Not Liable For Adverse Effects

This article was originally published in PharmAsia News

Executive Summary

Seven Chinese experts appointed by China's Ministry of Health and State FDA think that the adverse heparin incidents in the U.S and other countries cannot be conclusively attributed to impurities in heparin raw materials. The group met up with 11 international peers from the U.S., Australia, Denmark, Germany, France, Korea, Netherlands, Canada, Japan, Italy and Singapore to discuss heparin quality standards, testing methods, clinical side effects, source tracing and supply. Based on the following evidence, the Chinese experts surmised that the tainted heparin cannot be conclusively linked to the side effects. Injections produced by American firms Covidien and B.Braun, which used tainted heparin raw materials from China did not give rise to any bad reaction; on the other hand, some batches of Baxter's injections without the ingredients had caused serious side effects. (Click here for more - Chinese Language)

You may also be interested in...

How Significant Will Veklury’s Sales Be? Forecasts Show It Is Hard To Tell

Veklury is now the first US FDA-approved treatment for COVID-19, but its limited benefits means its lifespan as a blockbuster could be short.

Brexit: Life Science Firms In An ‘Impossible Position’

As negotiations between the UK and EU enter a crucial phase, the UK life sciences industry has called for more clarity and guidance on what companies can expect to face at the end of the Brexit transition period. 

Novartis Advances Novel Kidney Disease Therapy Iptacopan

Phase II results look good for one of the first-in-class product’s potential indications, C3 glomerulopathy. The product was highlighted late last year as an up-and-coming pipeline asset.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts